OTCMKTS:LOGC LogicBio Therapeutics Q3 2026 Earnings Date & Estimates $15.30 +0.01 (+0.07%) As of 10/26/2026 03:59 PM Eastern LogicBio Therapeutics is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, after market closes. The conference call is scheduled for 4:00 PM ET. Research:ProfileEarnings History Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 3, 2026TimeAfter Market ClosesConference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from LogicBio Therapeutics in Q3 2026LogicBio Therapeutics is expected to post earnings of -$0.0419 per share on revenue of $23.31 million. LogicBio Therapeutics last reported on August 13, 2026, posting -$0.14 per share and missing the -$0.0414 consensus estimate. LogicBio Therapeutics has beaten the consensus EPS estimate in 4 of its last 5 quarters.Consensus EstimatesConsensus EPS-$0.0419Expected Revenue$23.31 millionRecent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.14 (Missed by -$0.0986)Last Quarter Revenue$33.60 millionEPS Beat Rate4 of last 5 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2025 Earnings ReportQ4 2024 Earnings Report LogicBio Therapeutics Q3 2026 Earnings FAQ When does LogicBio Therapeutics report Q3 2026 earnings? LogicBio Therapeutics (OTCMKTS:LOGC) is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is LogicBio Therapeutics' Q3 2026 earnings call? LogicBio Therapeutics' Q3 2026 earnings conference call is scheduled for Tuesday, November 3, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for LogicBio Therapeutics? Analysts expect LogicBio Therapeutics to post earnings of -$0.0419 per share for Q3 2026. How much revenue is LogicBio Therapeutics expected to report? The consensus revenue estimate for LogicBio Therapeutics is $23.31 million for Q3 2026. LogicBio Therapeutics Earnings HeadlinesContextLogic Holdings Inc. Publishes Q&A Following Second Quarter 2026 ResultsAugust 21, 2026 | globenewswire.comContextLogic Holdings Inc. Reports Second-Quarter 2026 Financial ResultsAugust 13, 2026 | globenewswire.comWould Anthropic IPO Burst the Bubble?The biggest IPO in history is likely just weeks away… Anthropic, the company behind Claude AI, is rumoured to be lining up a Nasdaq debut before Thanksgiving… at a valuation of up to $2 trillion. But here’s what nobody’s talking about… A raise of about $100 billion doesn’t just make headlines. It puts an enormous spotlight on the AI industry. And as investors rush to find the next big opportunity in artificial intelligence, some of the most interesting plays may be hiding outside traditional AI stocks.October 27 at 1:00 AM | Crypto 101 Media (Ad)ContextLogic to Acquire gChem for $850 MillionAugust 5, 2026 | globenewswire.comContextLogic Appoints Seth Siegel as Senior AdvisorJuly 13, 2026 | globenewswire.comContextLogic Holdings Inc. Announces Scott Stewart as Chief Financial Officer & Chief Operating OfficerJune 1, 2026 | globenewswire.comSee More LogicBio Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like LogicBio Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LogicBio Therapeutics and other key companies, straight to your email. Email Address About LogicBio TherapeuticsLogicBio Therapeutics (OTCMKTS:LOGC) was a clinical-stage genetic medicine company focused on developing therapies for patients with serious genetic and metabolic diseases. The company’s research centered on genetic medicine technologies designed to address the underlying causes of disease rather than treat symptoms alone. LogicBio’s principal platform, GeneRide, was developed to enable the targeted insertion of therapeutic genes into the genome. The company also pursued GeneWare, a platform intended to support gene-editing applications. Its development programs included LB-001, an investigational treatment for methylmalonic acidemia, and additional programs targeting genetic disorders such as hemophilia. Founded in 2014 and headquartered in Lexington, Massachusetts, LogicBio operated as a biotechnology company serving the global genetic medicine market through research and clinical development activities. Fred Chereau served as the company’s president and chief executive officer during its publicly traded period. In 2022, Alexion, AstraZeneca’s rare-disease business, completed its acquisition of LogicBio. Following the transaction, LogicBio became a wholly owned subsidiary, and its standalone public-company operations and stock listing were discontinued.View LogicBio Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Lockheed Martin's F-35 Deal Could Change How Wall Street Values the StockIntel's $155 Price Target Raises a Bigger Question About Its Turnaround PotentialMerck and Moderna's Cancer Vaccine Worked—Who Gets Paid?GXO Logistics Is Turning Warehouse Robots Into a Growth StrategyAnthropic's IPO Filing Reveals a Massive Opportunity for AI Infrastructure GiantsA Solid Margin Story Means the Sell-Off in DECK May Be OverdoneBristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock Upcoming Earnings T-Mobile US (10/28/2026)Alphabet (10/28/2026)Alphabet (10/28/2026)Carvana (10/28/2026)eBay (10/28/2026)Garmin (10/28/2026)O'Reilly Automotive (10/28/2026)Equinor ASA (10/28/2026)Phillips 66 (10/28/2026)AON (10/28/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
